Leslie’S, Inc.
—- Market cap
- $4.99M
- Debt
- —
- Cash
- −$64.34M
Complete market value, debt and cash evidence is required for enterprise value.
Compare price, profitability, solvency, and SEC-reported financials side by side—before deciding which assumptions deserve a closer look.
FY 2025 · Mkt capMarket cap $4.99M · View financials
Snapshot Sep 10, 2026, 10:56 AM ET
FY 2025 · View financials
Decision snapshot: LESL stock price vs AMGN: inconclusive Relative valuation is incomplete for this pair. Review the available filing metrics before drawing a conclusion.
Quick read
Each company valued on the other's multiple, then compared with the market price.
Implied fair value · at AMGN's multiple
Needs AMGN P/S.
Implied fair value · at LESL's multiple
Price unavailable
Metric by metric
Where each company leads, and how wide the gap is.
Growth lag
Reported gross margin
Operating income + D&A
Lower is better
Not comparable
Lower leverage
Statements
Annual statements in reported currencies, with calculations and source evidence.
Values retain reported currencies and share bases. Select a figure to inspect its period, calculation and filing inputs. Differences require compatible units and periods.
Explore enterprise value and market valuation multiples in the valuation sections.
Trendline
Eight period-end years of reported revenue, earnings, and margins. Periods and currencies are shown with the data.
Price framework
USD market cap plus reported borrowing debt, less cash and equivalents. This EV proxy excludes investments, preferred stock and noncontrolling-interest adjustments.
Complete market value, debt and cash evidence is required for enterprise value.
Complete market value, debt and cash evidence is required for enterprise value.
Price framework
The same filing-backed model used on each company's valuation page, with company-specific inputs and calculated scenarios.
LESLIE’S, INC. · implied price per share
Latest annual free cash flow must be positive to qualify the filing-backed baseline.
Amgen Inc. · implied price per share
Bear
$98.66
Base
$130.87
Bull
$172.82
Balance sheet health
Inspect reported liquidity and leverage alongside historical financial-health checks.
Financial strength on a 0–9 scale.
Bankruptcy-risk signal from balance sheet and earnings power.
Comparable set
Where the pair sits against the wider comparable set.
Keep comparing
Open adjacent comparisons from the same industry to pressure-test the read across multiple pairs.
HOME DEPOT, INC.
LESL vs HD
LOWES COMPANIES INC
LESL vs LOW
O REILLY AUTOMOTIVE INC
LESL vs ORLY
TRACTOR SUPPLY CO /DE/
LESL vs TSCO
REGENERON PHARMACEUTICALS, INC.
LESL vs REGN
BIOGEN INC.
LESL vs BIIB
VERTEX PHARMACEUTICALS INC / MA
LESL vs VRTX
Gilead Sciences, Inc.
LESL vs GILD
Moderna, Inc.
LESL vs MRNA
Eli Lilly and Company
LESL vs LLY
Cash excludes investments. EBITDA is an operating-income-plus-D&A proxy. Missing borrowing categories remain unavailable; select a value to inspect its inputs.
LLM-powered synthesis
An explanation of the financial evidence. Check its snapshot date against the figures above.
This explanation uses an earlier data snapshot or evidence version. Review its generation date and the current figures, or refresh after signing in.
If you believe LESL can reverse revenue declines and restore positive operating margins, then a contrarian long could make sense because the stock already trades near its historical band; otherwise, the data support avoiding the name versus AMGN because LESL’s negative growth, negative profitability, and distress signals do not justify a AMGN-like multiple.
LESL trades at 0.1x P/S versus AMGN at 5.2x, which mechanically drives the huge implied-price gap. However, the comparison is distorted because LESL has negative margins, declining revenue, and negative earnings, while AMGN has strong profitability and growth.
Supporting Metrics